Ana Marcu

机构：Abterra Biosciences (United States) · ORCID：0000-0003-0808-8097

发表论文 56 篇 · 总被引 20896 次 · h-index 25

代表论文

• HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy (2021 · Journal for ImmunoTherapy of Cancer · 被引 256)
• BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity (2021 · The Journal of Experimental Medicine · 被引 76)
• Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues (2022 · iScience · 被引 51)
• Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types (2023 · Nature Biotechnology · 被引 49)
• PathBank 2.0—the pathway database for model organism metabolomics (2023 · Nucleic Acids Research · 被引 42)
• Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade (2022 · Science Immunology · 被引 41)